Hepatocellular carcinoma is a malignancy with poor clinical prognosis. Hepatic oval cells (HOCs) tend to differentiate into cancerous hepatocellular carcinoma cells (HCCs) in the tumor microenvironment. The purpose of the present study was to explore the role of kangxianruangan granule (KXRG)-containing serum in inhibiting the differentiation of HOCs into HCCs via the Wnt-1/beta-catenin signaling pathway. N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) was applied to induce the transformation of the rat HOC cell line WB-F344 into HCCs. The overexpression plasmid, Wnt-1-up, was utilized to increase Wnt-1 expression. Subsequently, high, medium and low concentrations of KXRG were applied to MNNG-treated WB-F344 cells to assess the inhibitory effect of KXRG on cell differentiation. Flow cytometry was conducted to detect the cell cycle distribution, apoptotic rate and expression of cytokeratin-19 (CK-19) protein in cells. An immunofluorescence double staining protocol was used to detect the expression of Wnt-1 and beta-catenin. ELISAs were performed to detect alpha fetoprotein in the cell supernatants. Reverse transcription-quantitative PCR and western blotting were conducted to detect the mRNA and protein expression levels of Wnt-1, beta-catenin, Cyclin D1, C-myc, matrix metalloproteinase-7 (MMP-7), Axin2 and epithelial cell adhesion molecule (EpCAM) in cells. Compared with the normal group, the apoptotic rate, proportion of S phase cells, concentration of AFP in the cell supernatant, level of CK-19 protein, and mRNA and protein expression levels of Wnt-1, beta-catenin, Cyclin D1, C-myc, MMP-7, Axin2 and EpCAM were all significantly increased in the model group. Addition of KXRG significantly reduced the aforementioned indicators compared with the model group. Moreover, Wnt-1 overexpression further increased the aforementioned indicators compared with the model group, whereas KXRG significantly inhibited these effects. The results indicated that KXRG inhibited the differentiation of HOCs into HCCs via the Wnt-1/beta-catenin signaling pathway, which suggested the potential clinical application of KXRG for the prevention of hepatocellular carcinoma.

目的 观察补肾生髓成肝方加减联合聚乙二醇干扰素α-2b治疗慢性乙型肝炎(CHB)的效果及对患者肝功能、肝纤维化的影响.方法 采用随机数字表法将2017年9月至2019年12月湖北省中医院收治的70例CHB患者分为观察组(35例)和对照组(35例).对照组予以聚乙二醇干扰素α-2b治疗,观察组予以补肾生髓成肝方加减联合聚乙二醇干扰素α-2b治疗,比较两组中医症候评分,治疗前后肝功能指标[血清总胆红素(TBil)、丙氨酸氨基转移酶(ALT)、天门冬酸氨基转移酶(AST)、血清白蛋白(ALB)],肝纤维化指标[Ⅲ型前胶原(PCⅢ)、Ⅳ型胶原(Ⅳ-C)、层粘连蛋白(LN)、透明质酸酶(HA)],乙肝病毒标志物[ALT复常率、乙型肝炎病毒(HBV)-DNA转阴率及乙型肝炎e抗原(HBeAg)阴转率]及不良反应发生情况.结果 治疗前两组中医症候评分比较,差异无统计学意义(P＞0.05);治疗后两组中医症候评分较治疗前降低,且观察组低于对照组(P＜0.05).治疗前两组肝功能指标(TBil、ALT、AST、ALB)比较,差异无统计学意义(P＞0.05);治疗后两组ALB水平较治疗前升高,TBil、ALT、AST水平降低,且观察组ALB水平高于对照组,TBil、ALT、AST水平低于对照组(P＜0.05).治疗前两组肝纤维化指标(PCⅢ、Ⅳ-C、LN、HA)比较,差异无统计学意义(P＞0.05);治疗后两组PCⅢ、Ⅳ-C、LN、HA水平较治疗前降低,且观察组低于对照组(P＜0.05).随访6个月,观察组HBeAg阴转率高于对照组(P＜0.05);两组患者不良反应发生率比较,差异无统计学意义(P＞0.05).结论 补肾生髓成肝方加减联合聚乙二醇干扰素α-2b治疗CHB有助于改善患者肝功能和肝纤维化,效果显著,安全性好,值得在临床上推广应用.

新冠肺炎防控正处于关键时期.湖北省中医院‘省科技厅新型肺炎应急科技攻关项目”负责人巴元明教授率领医院新冠肺炎防控指挥部医疗救治组组长李晓东、副组长闵晓俊、程业刚、第一批发热门诊、隔离病房主任、副主任集体制定了《湖北省中医院新型冠状病毒肺炎中医药防治方案》(第三版),在指导临床治疗新型冠状病毒肺炎中取得了良好疗效.

目的:观察"肺炎1号"治疗新型冠状病毒肺炎的临床疗效.方法:选取2020年2月17日至2020年3月15日湖北省中医院、监利县中医院、蕲春县人民医院、潜江市中医院、洪湖市中医医院、阳新县中医医院、浠水县中医院、大冶市中医医院、汉川市人民医院、武昌方舱医院收治的新型冠状病毒肺炎患者451例,采用"肺炎1号"联合西医常规治疗,观察"肺炎1号"对新型冠状病毒肺炎患者的临床症状、舌象、实验室检查结果及肺部CT情况.结果:共纳入451例患者,其中轻型21例,普通型378例,重型46例,危重型6例.疑似病例6例(1.33％),临床诊断病例168例(37.25％),确诊病例277例(61.42％).治疗后与治疗前比较,患者发热、咳嗽、乏力主要症状发生率显著降低(P<0.05);恶寒、鼻塞、流涕、打喷嚏、咽部痒、咽痛、呼吸困难、胸闷、肌肉酸痛或关节疼痛、头晕头痛、纳差、恶心呕吐、腹胀、大便稀溏症状发生率显著改善(P<0.05);白细胞计数、中性粒细胞绝对值变化差异无统计学意义(P>0.05);淋巴细胞绝对值明显升高,差异有统计学意义(P<0.05);C反应蛋白、降钙素原明显降低,差异有统计学意义(P<0.05).退热时间3(1～3.25)d.229例患者舌质由红或绛逐渐转为淡红,好转率为75.58％;177例患者白腻苔、厚腻苔、黄腻苔明显变薄,好转率为65.31％.新型冠状病毒核酸转阴时间为8(5,11)d.415例(92.02％)肺部CT明显好转,主要表现在病灶面积减小,变薄变淡.达到出院标准430例,临床治愈率95.34％;好转15例;无效3例;死亡3例(0.67％).治疗过程中,未见明显不良反应,临床应用安全.结论:"肺炎1号"结合西医常规治疗对新型冠状病毒肺炎有较好的治疗作用,能够快速稳定病情,阻断轻型、普通型向重型、危重型转化;明显改善患者临床症状;较好促进肺部炎性反应吸收;使用安全可靠.

目的:观察“肺炎1号”治疗2019冠状病毒病(COVID-19)的临床疗效,为进一步指导临床救治提供依据.方法:选择2020年2月17日至29日湖北省中医院收治的新型冠状病毒肺炎患者69例,采用“肺炎1号”联合西医常规治疗,观察“肺炎1号”对COVID-19患者的临床症状、舌象、实验室检查结果及肺部CT改善情况.结果:共纳入69例患者,其中轻型1例,普通型66例,重型2例.新型冠状病毒核酸检测阳性48例(69.57％)、疑似2例(2.90％)、阴性19例(27.54％).肺部CT肺纹理增多、增粗4例(5.80％),可见斑片影、磨玻璃样改变65例(94.20％).治疗后,超敏C反应蛋白较治疗前显著降低(P＜0.05).患者发热、咳嗽、乏力等相关症状较治疗前显著好转(P＜0.01).退热时间最短1d,最长10d,平均(3.91±1.93)d.40例患者舌质红或绛逐渐转淡红,好转率为83.33％;34例患者白腻苔、厚腻苔、黄腻苔明显变薄,好转率为75.56％.新型冠状病毒核酸检测转阴时间最短2d,最长14d,平均(7.29±3.41)d.肺部CT病灶面积减小,变薄变淡,60例(86.96％)较前好转.纳入的69例患者,由普通型转重型2例(3.03％),无死亡病例,全部治愈出院.“肺炎1号”无明显不良反应.结论:“肺炎1号”结合西医常规治疗对COVID-19有较好的治疗作用,能快速稳定病情,阻断轻型、普通型向重型、危重型转化,改善患者症状且使用安全.

目的 分析“肺炎1号”联合西医常规治疗新型冠状病毒肺炎(COVID-19)的临床疗效.方法 按治疗方法的不同,将使用“肺炎1号”治疗的173例COVID-19患者作为“肺炎1号”治疗组,单纯使用西医常规治疗的105例患者作为西医对照组.观察两组患者的临床疗效相关指标,包括临床症状、退热时间、核酸转阴时间、白细胞计数、淋巴细胞绝对值、中性粒细胞绝对值、超敏C反应蛋白、降钙素原、肺部CT、病情转归等.结果 治疗后,两组患者发热、乏力主要症状较治疗前显著降低且有显著性差异(P＜0.05).西医对照组治疗后咳嗽较治疗前无显著性差异,“肺炎1号”治疗组治疗后较治疗前明显改善,且有显著性差异(P＜0.05),与西医对照组治疗后对比有显著性差异(P＜0.05).在改善患者乏力、咳嗽方面,“肺炎1号”治疗组明显优于西医对照组(P＜0.05).治疗后西医对照组咽部不适、纳差、呼吸困难、胸闷、恶寒、头晕、头痛症状较治疗前显著改善且有显著性差异(P＜0.05),“肺炎1号”治疗组咽部不适、纳差、呼吸困难、胸闷、呕吐、恶心、肌肉酸痛、关节疼痛、大便稀溏、恶寒、头晕、头痛、鼻塞、流涕、打喷嚏症状较治疗前显著改善且有显著性差异(P＜0.05).同西医对照组相比,在改善咽部不适、纳差、呕吐、恶心方面“肺炎1号”治疗组更为明显(P＜0.05).在症状积分方面,两组治疗后均明显降低,且有显著性差异(P＜0.05),“肺炎1号”治疗组治疗后优于西医对照组治疗后,有显著性差异(P＜0.05).治疗后,两组白细胞计数、淋巴细胞绝对值与治疗前比较有显著性差异(P＜0.05),且“肺炎1号”治疗组治疗后与西医对照组治疗后比较有显著性差异(P＜0.05).两组C反应蛋白治疗后与治疗前比较明显降低,有显著性差异(P＜0.05),且“肺炎1号”治疗组治疗后与西医对照组治疗后比较有显著性差异(P＜0.05).两组降钙素原治疗后无显著性差异(P＞0.05).两组退热时间、新型冠状病毒核酸转阴时间有显著性差异(P＜0.05).西医对照组95例(90.48％)肺部CT较前好转,“肺炎1号”治疗组160例(92.49％)肺部CT较前好转,两组比较无显著性差异(P＞0.05),均主要表现在病灶面积减小,变薄变淡.在总有效率方面,西医对照组为87.62％,“肺炎1号”治疗组为94.80％,“肺炎1号”治疗组的总有效率明显高于西医对照组,且有显著性差异(P＜0.05).在死亡率方面,西医对照组死亡4例(3.81％),“肺炎1号”治疗组死亡1例(0.58％),西医对照组的死亡率高于“肺炎1号”治疗组,无显著性差异(P＞0.05).在轻型、普通型向重型、危重型转化方面,西医对照组转重症8例(7.62％),“肺炎1号”治疗组转重症3例(1.73％),西医对照组明显高于“肺炎1号”治疗组(P＜0.05).结论 “肺炎1号”能缩短退热时间、新冠病毒核酸转阴的时间,缓解患者的临床症状,较好促进肺部炎症吸收,提高治愈率,阻断轻型、普通型向重型、危重型转化,且使用安全可靠.

目的:分析新型冠状病毒肺炎（COVID-19）辨证论治的临床疗效,旨在为COVID-19的诊断和治疗提供参考.方法:以湖北省中医院和汉川市人民医院收治的105例COVID-19患者作为研究对象,采用中医辨证论治方法,观察证候分型,临床治愈率,转重率,退热时间,核酸转阴时间,症状体征、实验室检查和肺部CT影像改善情况.结果:105例患者中确诊病例88例（83.81%）,临床诊断病例17例（16.19%）.包括普通型82例（78.10%）,重型23例（21.90%）.其中湿热袭肺证13例（12.38%）,邪犯少阳、湿热壅肺证72例（68.57%）,痰热壅肺证20例（19.05%）.全部患者采用中医辨证论治联合西医常规治疗,总体临床治愈率为95.24%;普通型向重型及危重型转化2例（2.44%）.平均退热时间为2～5 d,平均3 d.乏力、发热、咳嗽、咳痰、呼吸困难主要症状发生率较治疗前明显降低（P＜0.05）;胸闷、纳差、肌肉酸痛或关节疼痛、咽痛、鼻塞流涕等症状发生率较治疗前均明显降低（P＜0.05）;舌红或绛,苔黄、厚腻的发生率较治疗前均明显降低（P＜0.05）;苔色白的发生率较治疗前明显升高（P＜0.05）.实验室检查:白细胞计数、淋巴细胞绝对值均较治疗前明显升高（P＜0.05）;C反应蛋白较治疗前明显降低（P＜0.05）.新型冠状病毒核酸转阴时间为5～12 d,平均8 d.95例（90.48%）患者的肺部CT明显好转,主要表现在影像学病灶面积减小、变薄变淡.本组中医辨证论治的中西医结合方法未见不良反应,临床应用安全.结论:COVID-19患者初期表现为湿热袭肺证,中期表现为邪犯少阳、湿热壅肺证或痰热壅肺证.中医辨证论治COVID-19临床疗效确切,能够阻断普通型向重型及危重型转化,明显改善患者临床症状,快速促进肺部炎症吸收,疗效安全可靠.

新型冠状病毒肺炎属于中医学"疫病"范畴.疫情爆发以来,全国各省市卫生行政管理部门坚持中西医结合原则,陆续制定了各省市的中医药防治方案,三因制宜,分期分型辨证并不断完善.笔者全面收集并整理相关信息,基于病因病机分析了各省市中医药防治方案,认为此次疫病是外感疫气,病位主要在肺卫,病邪主要表现为"毒、湿、热、虚、寒".此"毒"即为疫气,武汉遇暖冬,非其时而有其气而发疫,一气一病,播散流行,治疫必先治毒;"湿"邪之地在南北方各占一半,东西部均有,在南方源于季节和地域,在北方可由寒挟杂,治疗均应祛湿;"热"主要见于南方,为南方常见的病邪,亦可因湿毒入里,湿郁化热,而在北方热与湿同现,主要是因湿毒入里,湿郁化热,治热均以清为主;"虚"则主要在北方,北方冬季多寒,易伤正致虚,或邪正交争激烈,伤阳伤阴致虚,宜祛邪为标,扶正为本;"寒"见于北方和南方山区,寒气过甚,易伤阳伤正,故尤其要注重预防,且以补正气为主.中医防疫治疫应三因制宜,重视预防,与时俱进.

目的 探讨葛根芩连丸治疗新型冠状病毒肺炎(COVID-19)的临床疗效.方法 选择2020年2月23日-3月15日湖北省中医院收治的COVID-19患者,最终共纳入118例,按治疗方法随机分为对照组60例与治疗组58例.对照组给予常规治疗,治疗组在对照组治疗的基础上加用葛根芩连丸口服,每天3次,每次1包.观察两组退热时间、核酸转阴时间、转重症率、死亡率、临床疗效及治疗前后症状积分、肺部CT的改变.结果 两组患者治疗后发热、咳嗽、乏力等主要症状较治疗前显著改善(P<0.05).治疗组在改善咳嗽、胸闷、恶心、呕吐、大便稀溏方面更为明显(P<0.05).两组胃肠道症状积分和症状总积分较治疗前均明显降低(P<0.05),且治疗后两组间有显著性差异(P<0.05).治疗组舌质、舌苔的改善比对照组更加明显(P>0.05).治疗后,对照组白细胞计数、淋巴细胞绝对值与治疗前比较有显著性差异(P<0.05),且治疗后两组间有显著性差异(P<0.05).治疗后两组hs-CRP明显降低(P<0.05),两组间有显著性差异(P<0.05).两组退热时间无显著性差异(P>0.05).两组新型冠状病毒核酸转阴时间有显著性差异(P<0.05).对照组与治疗组肺部CT均较前好转,且无显著差异(P>0.05);两组患者在出院达标方面无明显差异,且均未出现无效、死亡以及向重型危重型转化等病例.治疗过程中未见不良反应,临床应用安全性良好.结论 葛根芩连丸能积极改善COVID-19患者临床症状,对胃肠道症状有较好的治疗作用,使用安全可靠,值得在临床进一步推广.

"见肝之病,知肝传脾,当先实脾"源自《难经》,是中医治疗肝病的理论精髓,指导临床治疗各种肝病.本文从肝与脾两脏生理、病理关系分"肝病实脾"之意,阐述对"肝病实脾"的认识,并结合各医家观点分析脂肪肝病因病机,明确"肝病实脾"在脂肪肝治疗中的重要性,另通过例举临床病案,证明"肝病实脾"治疗脂肪肝的疗效.

The thorns of Gleditsia sinensis have been historically used in Chinese medicine and are considered one of the fundamental therapeutic herbs. Its anticancer effects are currently being explored. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and still requires the development of new drugs with higher efficiency. By using a rat HCC model implanted with cancerous Walker-256 cells, the therapeutic effects of G. sinensis extract (GSE) were assessed, as well as its regulatory effects on miRNAs. GSE significantly restored liver morphology and dramatically induced cell apoptosis in HCC rats. In addition, miR-21/181b/183 was upregulated in the HCC liver, and the elevation of these miRNAs could be alleviated by both GSE and sorafenib. PTEN/TIMP3/PDCD4 downregulation was consistent with the targets of miR-21/181b/183 in the HCC liver, and the alteration of these target genes was restored by both GSE and sorafenib. TIMP3 effects on MMP-2/9 expression were also determined. Our present findings indicate the potential of GSE in HCC treatment, and expand the understanding of miRNA-related mechanisms in the anticancer effects of GSE.

目的:基于真实世界临床数据,观察体现“补肾生髓成肝”治疗法则的地五养肝方治疗原发性胆汁性胆管炎(PBC)的临床疗效.方法:回顾性收集2014年1月至2018年6月在我院诊疗的71例PBC患者临床资料,其中采用地五养肝方联合熊去氧胆酸(UDCA)治疗的38例为治疗组,采用UDCA治疗的33例为对照组.治疗24周时,观察并比较两组患者治疗前后各生化指标(ALT、AST、GGT、TBil、ALP)、肝脏硬度值、证候积分变化,并比较两组患者的临床疗效.结果:两组患者治疗后ALT、AST、GGT、TBil、ALP水平、肝脏硬度值、证候积分与本组治疗前比较,差异均有显著性意义(P＜0.05);治疗后治疗组患者在完全反应、部分生化指标(GGT、TBil)改善、肝脏硬度值下降、证候积分减少方面均优于对照组,差异有显著性意义(P＜0.05),其临床疗效优于对照组.结论:体现补肾生髓成肝治疗法则的地五养肝方治疗PBC患者具有良好的临床效果.

目的 对中医综合疗法治疗代偿期肝硬化的临床效果进行分析和评价.方法 以我院2016年2月至2017年2月接治的96例代偿期肝硬化患者作为本研究的对象,基于就诊单双号分成探究组和对比组,均为48例;对比组应用常规西药治疗,探究组采取中医综合疗法,连续治疗3周后,对比分析两组患者的治疗总有效率及肝功能改善情况.结果 探究组治疗总有效率为93.7％,对比组为83.3％,差异有统计意义(P<0.05);治疗后,两组患者的肝功能指标均得到改善,但探究组的改善效果更优于对比组(P<0.05).结论 采取中医综合治疗代偿期肝硬化效果确切,可有效改善患者肝功能,安全性高,值得临床应用.

The number of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) has shown a significant upward trend in recent years. However, antiviral drugs are not very effective. Regulation of liver regeneration by traditional Chinese medicine is an important way to improve clinical efficacy. This randomized controlled trial assessed the efficacy and safety of DWYG in patients with HBeAg-negative CHB. Overall, 130 subjects were randomized to (A) DWYG 1.2 g three times daily (n = 44), (B) entecavir 0.5 mg/day (n = 43) in combination with DWYG or (C) entecavir 0.5 mg/day (n = 43). The liver histological response rate was assessed as the primary efficacy endpoint. The results showed that the liver histological response rate in the combination treatment group was significantly higher than that in the group with entecavir (71.43% versus 22.22%; P = 0.036) after 48 weeks of treatment. And the pathological progression rate of liver in the group with DWYG was significantly lower than that of the entecavir group during 228 weeks of follow-up (0% versus 60.00%; P = 0.019). No significant adverse events occurred during the study. In conclusion, treating HBeAg-negative CHB with DWYG is safe and effective to improve liver histological response.

Objective:To study the mechanism of anti-hepatic fibrosis through Kangxian Ruangan granule regulating the Hedgehog (Hh) signaling pathway which activated Hepatic Stellate Cells (HSC) and inhibiting the activation of HSC.Methods:To introduce Human Hepatic Stellate Cell line HSC-LX2,culture and passage them in conventional methods.The expertment was divided into blank control group,model group and Kangxian Ruangan granule medium,low does group.Conventional cultured cells as the blank control group.For 24 hours.Followed,the cells were collected.The expression of Hh signaling pathway's related signal molecules such as Gli1,Shh,Ptc and Smo and the effect of Kangxian Ruangan granule on HSC activation and synthesis of transforming growth factor-beta 1 (TGF-1) and PDGF-B were analyzed.Results:Compared with the blank control group,the expression of Hh signaling pathway's related signal molecules include Shh,Ptc,Smo,Gli1 mRNA were increased in HSC cells of the model group,the difference was significant (P ＜ 0.05);The expression of Shh,Ptc,Smo,Gli1 mRNA in Kangxian Ruangan granule medium,low does group were lower than that in the model group (P ＜ 0.05),and there was no significant difference among different does groups;Compared with the blank control group,the synthesis of TGF-β1 and PDGF-B increased after HSCs activated by PDGF-BB in the model group (P ＜ 0.05).Compared with the model group,the synthesis of TGF-β1 and PDGF-B decreased in Kangxian Ruangan granule medium,low does group (P ＜ 0.05).Conclusion:Kangxian Ruangan granule could regulate the expression of nuclear transcription factor Gli1 and its related signal molecules include Shh,Ptc and Smo of Hedgehog (Hh) signal pathway,and then inhibit the activation of HSCs and reduce the synthetise of TGF-β1and PDGF-B.

Objective To explore the effect of Kang'ai injection in patients with hepatocellular carcinoma treated with trancatheter arterial chemoembolization (TACE) combined with microwave ablation (MWA). Method 92 cases of patients with hepatocellular carcinoma treated by TACE combined with MWA were retrospectively analyzed, patients in study group (n=46) were administered with TACE + WMA+ Kang'ai injection, while those in control group (n=46) were given TACE + WMA only, the levels of AFP, ALT, coagulation function, overall response rate and adverse reac-tions were compared between the two groups before and after treatment. Result There was no significant difference in AFP, ALT and coagulation function between the two groups before treatment (P>0.05);while after treatment, the levels of ALT and AFP in the study group were lower than those in the control group (P<0.05);the overall response rate was higher in the study group than control group (P<0.05);during the therapy, the study group had lower incidence of leuko-penia and decreased hemoglobin compared with control group (P<0.05). Conclusion Kang'ai injection enhances the overall response rate for patients with hepatocellular carcinoma receiving TACE combined with MWA, thus reduces the damage to liver function and adverse reactions induced by the medications.

Objective It is to investigate the effect of traditional Chinese medicine of clearing-heat removing blood-stasis on the treatment of acute intrahepatic cholestasis of liver and gallbladder damp heat syndrome and its influence on the levels of inflammatory cytokines, SOD and MDA.Methods 100 patients with acute intrahepatic cholestasis of liver and gallbladder damp heat syndrome were randomly divided into 2 groups with 60 cases in each, the patients were treated with western medicine in the control group, and with traditional Chinese medicine of clearing-heat removing blood-stasis on the basis of the treatment of the control group in the observation group.The changes of TCM syndrome score, the levels of liver function indexes, inflammatory cytokines, SOD and MDA before and after treatment were observed, the short-term effect and adverse reactions of the two groups were analyzed.Results After treatment, the scores of eye yellow, hypochondriac pain, abdominal distension nausea, hot upset, dry and bitter taste in mouth, yellow urination, and liver function index, inflammatory cytokine levels in the two groups were significantly decreased than those before treatment (all P<0.05), and those of the observation group were significantly lower than the control group (all P<0.05);the levels of SOD and MDA in the two groups were significantly better than those before treatment (all P<0.05), and those of the observation group were significantly better than the control group (P<0.05);the total effective rate of the observation group was significantly higher than the control group (P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion The traditional Chinese medicine of clearing-heat removing blood-stasis can effectively relieve the symptoms and signs in the treatment of acute intrahepatic cholestasis of liver and gallbladder damp heat syndrome, improve liver function, regulated the levels of inflammatory cytokines and SOD and MDA, and do not increase the risk of adverse reactions.

目的：观察解毒舒肝片对HBeAg阴性慢性乙肝患者的治疗作用。方法：将60例HBeAg阴性慢性乙肝患者随机分为治疗组和对照组，治疗组32例给予解毒舒肝片，对照组28例给予阿拓莫兰片、五酯滴丸。在0周、12周、24周检测HBV-DNA、ALT、AST水平及进行安全性评价。结果：两组在12周及24周ALT、AST均较治疗前明显下降(p<0.05)。治疗组在12周及24周HBV-DNA较治疗前明显下降(p<0.05)，24周时HBV-DNA下降较对照组明显(p<0.05)。治疗组24周HBV-DNA阴转率为28.12%，对照组为7.14%。结论：解毒舒肝片能够在一定程度上抑制HBeAg阴性慢性乙肝患者HBV-DNA复制，促进肝功能恢复，具有治疗HBeAg阴性慢性乙肝作用，且安全性良好。